Featured Abstracts and Author Insights

---

ACG 2024 Newsworthy Abstracts Highlight Cutting-Edge Clinical GI Science

EMBARGO: All research presented at ACG 2024 is strictly embargoed until 12:00 pm ET on Sunday, October 27, 2024.

This page is a gateway to explore the clinical GI science featured at the 2024 ACG Annual Scientific Meeting. Here you will find award-winning abstracts, commentary and perspective from select authors of newsworthy findings, and tips to navigate the array of clinical research being presented at ACG 2024 by investigators working to advance digestive health and improve patient care.

The authors of ACG’s Newsworthy Abstracts, selected by the ACG Public Relations Committee, provide additional perspective on their findings and explain what the clinical science means for patients. Following the links below, reporters can explore these Newsworthy Abstracts and author insights and connect with these researchers for media stories.

To review all ACG Press Releases, visit Media Statements.

• ACG 2024 Conference Platform
  • Tip: the online Conference Platform will allow you to search all abstracts and access the full text for both Plenary and poster presentations.
• Newsworthy Abstracts
  • Explore some of the papers and presentations below, selected by reviewers from ACG’s Educational Affairs and Public Relations Committees, a distinguished group of experts who suggested papers and posters with innovative, newsworthy, and/or significant findings.

Nominated by the ACG Public Relations Committee, this group of abstracts features scientific findings that are innovative, newsworthy for the lay reader, relevant to those who suffer from common GI problems, and which represent a significant advancement in the diagnosis and treatment of GI diseases. The Committee aims to identify novel and thought-provoking abstracts which reinforce key public health messages, discuss emerging research that could inform and improve patient care (particularly for minority and at-risk populations), or which feature common GI problems in a new way.

Newsworthy Abstracts

= ACG Award Winner

• Oral 9 Rifaximin Monotherapy Is More Effective Than Lactulose Monotherapy for Reducing the Risk of Overt Hepatic Encephalopathy (OHE) Recurrence and All-Cause Mortality: An Analysis of Two Randomized Trials 
• Oral 12 Artificial Intelligence-Assisted Colonoscopy Is Associated With Higher Conversions From Screening to Therapeutic Exams 
• Oral 36 Automated Methods for Post-Procedure Follow-Up are Effective and Reduce Workload
• Oral 52 GLP-1 Receptor Agonists and Pancreatic Cancer Risk in Drug-Naive Patients With Type 2 Diabetes 
• Oral 66 Major Adverse Cardiovascular Events in Patients With IBD Taking Anti-TNF vs JAK Inhibitors: A Propensity Matched Cohort Analysis
• Oral 67 Impact of Gender-Affirming Hormone Therapy in Transgender and Gender Non-Conforming Patients Trial
• P1911 Optical Accuracy of Artificial Intelligence Large Language Models in Classifying Colorectal Polyps Based on Shape, Size, and Histology, Using Endoscopic Images
• P2134 Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) Use Reduces Risk of Early-Onset Colorectal Cancer in Patients with Type 2 Diabetes-Mellitus (T2DM) 
• P2357 Hormone Replacement Therapy Is Associated With Increased Risk of Developing Irritable Bowel Syndrome in Post-Menopausal Women 
• P3334 Elevated Rate of Gastric Cancer in Native American and Native Alaskans in Alaska Compared to in Other Regions
• P3828 Impact of Neighborhood-Level Transportation Insecurity on Colorectal Cancer Screening in the United States 
• P3865 Rising Mortality of Early-Onset Colorectal Cancer Particularly in Patients Younger Than 45 Years: Insights From the Largest Mortality Databases in the US Over Two Decades
• P3911 Efficacy and Pharmacokinetic Results From Ongoing Dose Escalation in RESOLVE, a Phase 1b/2a Study of EP-104GI (Extended-Release Fluticasone Propionate Intra-Esophageal Injection) for Eosinophilic Esophagitis